Sign in to view content

Outcomes of Patients with DME and Baseline BCVA 20/50 or Worse or 20/40 or Better Treated with Aflibercept 8 mg and 2 mg in the Phase 2/3 PHOTON Trial

Diana V Do, MD, FASRS

Video
Published 2024

Related

Vision Threatening Complications in Patients With Diabetic Macular Edema: A Post Hoc Analysis of the VISTA and VIVID Trials
Diana V Do, MD, FASRS
Annual Meeting Talks
2019
Intravitreal Gene Therapy for Neovascular AMD with ADVM-022: Results of the Phase 1 OPTIC Trial
Dante Joseph Pieramici, MD
Annual Meeting Talks
2021
Fluctuations in Central Subfield Thickness Associated With Worse Visual Outcomes in Patients With Diabetic Macular Edema in Clinical Trial Setting
Matthew Starr, MD
Updates from the Field
2021

Category: Retinal Vascular Disease

See more